ATHA insider transaction filings
Athira Pharma, Inc. — 29 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-01-05. Screen ATHA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-01-05 | 4 | Renninger Robert — Chief Financial Officer | Grant/award (A): 1,000 @ $2.31 · Option exercise (M): 1,236 @ $0 · Sale (S): 297 @ $6.88 · Option exercise (M): 1,236 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Worthington Mark — General Counsel and CCO | Option exercise (M): 3,667 @ $0 · Sale (S): 876 @ $6.88 · Option exercise (M): 3,667 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | CHURCH KEVIN — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 1,000 @ $2.31 · Option exercise (M): 3,667 @ $0 · Sale (S): 876 @ $6.88 · Option exercise (M): 3,667 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | San Martin Javier — CHIEF MEDICAL OFFICER | Option exercise (M): 4,667 @ $0 · Sale (S): 1,644 @ $6.88 · Option exercise (M): 4,667 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Litton Mark James — President and CEO, Director | Option exercise (M): 10,834 @ $0 · Sale (S): 2,586 @ $6.88 · Option exercise (M): 10,834 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Renninger Robert — Chief Financial Officer | Grant/award (A): 34,358 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Worthington Mark — General Counsel and CCO | Grant/award (A): 34,358 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | CHURCH KEVIN — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 35,138 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | San Martin Javier — CHIEF MEDICAL OFFICER | Grant/award (A): 44,508 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Litton Mark James — President and CEO, Director | Grant/award (A): 133,526 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | PERCEPTIVE ADVISORS LLC — Director, 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — Director, 10% owner EDELMAN JOSEPH — Director, 10% owner Perceptive Xontogeny Venture Fund II, LP — Director, 10% owner | Grant/award (A): 989,270 @ $6.35 · Grant/award (A): 329,756 @ $6.35 · Grant/award (A): 1,372,935 (derivative) @ $6.35 · Grant/award (A): 3,838,583 (derivative) @ $6.35 · Grant/award (A): 3,543,307 (derivative) @ $6.35 · Grant/award (A): 457,645 (derivative) @ $6.35 · +3 more | EDGAR |
| 2025-07-02 | 4 | CHURCH KEVIN — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 10,000 @ $0.23 · Option exercise (M): 36,666 @ $0 · Sale (S): 8,526 @ $0.29 · Option exercise (M): 36,666 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | San Martin Javier — CHIEF MEDICAL OFFICER | Option exercise (M): 46,666 @ $0 · Sale (S): 10,842 @ $0.29 · Option exercise (M): 46,666 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Worthington Mark — General Counsel and CCO | Option exercise (M): 36,666 @ $0 · Sale (S): 8,526 @ $0.29 · Option exercise (M): 36,666 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Renninger Robert — SVP, Finance and Accounting | Grant/award (A): 10,000 @ $0.23 · Option exercise (M): 12,359 @ $0 · Sale (S): 2,897 @ $0.29 · Option exercise (M): 12,359 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Litton Mark James — President and CEO, Director | Option exercise (M): 108,334 @ $0 · Sale (S): 25,123 @ $0.29 · Option exercise (M): 108,334 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Panzara Michael A. — Director | Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Romano Kelly A — Director | Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Kosacz Barbara — Director | Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | PICKERING GRANT — Director | Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | JOHNSON JAMES A — Director | Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | FLUKE JOHN M JR — Director | Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | EDELMAN JOSEPH — Director | Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4/A | Renninger Robert — SVP, Finance and Accounting | Grant/award (A): 73,350 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Renninger Robert — SVP, Finance and Accounting | Grant/award (A): 58,500 (derivative) @ $0 · Grant/award (A): 73,350 (derivative) @ $0 · Grant/award (A): 39,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | CHURCH KEVIN — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 87,845 (derivative) @ $0 · Grant/award (A): 58,563 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | San Martin Javier — CHIEF MEDICAL OFFICER | Grant/award (A): 111,270 (derivative) @ $0 · Grant/award (A): 74,180 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Worthington Mark — General Counsel and CCO | Grant/award (A): 85,895 (derivative) @ $0 · Grant/award (A): 57,263 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Litton Mark James — President and CEO, Director | Grant/award (A): 333,815 (derivative) @ $0 · Grant/award (A): 222,543 (derivative) @ $0 | EDGAR |
Recent 8-K events — Athira Pharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K/A | 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ATHA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →